NO20052039L - Fremgangsmater og sammensetninger for behandling av lupus ved anvendelse av clorfarabine - Google Patents

Fremgangsmater og sammensetninger for behandling av lupus ved anvendelse av clorfarabine

Info

Publication number
NO20052039L
NO20052039L NO20052039A NO20052039A NO20052039L NO 20052039 L NO20052039 L NO 20052039L NO 20052039 A NO20052039 A NO 20052039A NO 20052039 A NO20052039 A NO 20052039A NO 20052039 L NO20052039 L NO 20052039L
Authority
NO
Norway
Prior art keywords
treatment
methods
chlorfarabine
lupus
compositions
Prior art date
Application number
NO20052039A
Other languages
English (en)
Norwegian (no)
Inventor
Christopher B Wood
Stuart William Gordon Smith
Original Assignee
Bioenvision Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bioenvision Inc filed Critical Bioenvision Inc
Publication of NO20052039L publication Critical patent/NO20052039L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Transplantation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
NO20052039A 2002-09-27 2005-04-26 Fremgangsmater og sammensetninger for behandling av lupus ved anvendelse av clorfarabine NO20052039L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US41468502P 2002-09-27 2002-09-27
PCT/US2003/030407 WO2004028463A2 (fr) 2002-09-27 2003-09-25 Techniques et compositions destinees au traitement du lupus utilisant la clofarabine

Publications (1)

Publication Number Publication Date
NO20052039L true NO20052039L (no) 2005-06-23

Family

ID=32043398

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20052039A NO20052039L (no) 2002-09-27 2005-04-26 Fremgangsmater og sammensetninger for behandling av lupus ved anvendelse av clorfarabine

Country Status (6)

Country Link
US (2) US20060135463A1 (fr)
EP (1) EP1551386A4 (fr)
AU (1) AU2003276987B2 (fr)
CA (1) CA2500091A1 (fr)
NO (1) NO20052039L (fr)
WO (1) WO2004028463A2 (fr)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060270707A1 (en) * 2005-05-24 2006-11-30 Zeldis Jerome B Methods and compositions using 4-[(cyclopropanecarbonylamino)methyl]-2-(2,6-dioxopiperidin-3-yl)isoindole-1,3-dione for the treatment or prevention of cutaneous lupus
EP2029664A4 (fr) 2006-05-31 2015-09-09 Dow Global Technologies Llc Adjuvants pour emploi de l'énergie micro-onde dans le chauffage sélectif de systèmes polymères thermoplastiques
CN100591330C (zh) * 2007-08-23 2010-02-24 江苏奥赛康药业有限公司 一种氯法拉滨冻干粉针剂及其制备方法
KR100999798B1 (ko) * 2010-02-11 2010-12-08 엘지이노텍 주식회사 반도체 발광소자 및 그 제조방법

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3536809A (en) * 1969-02-17 1970-10-27 Alza Corp Medication method
US3598123A (en) * 1969-04-01 1971-08-10 Alza Corp Bandage for administering drugs
US3928319A (en) * 1971-06-16 1975-12-23 Syntex Inc 4 -Fluoro nucleosides, novel intermediates and methods of preparing same
US3845770A (en) * 1972-06-05 1974-11-05 Alza Corp Osmatic dispensing device for releasing beneficial agent
US3916899A (en) * 1973-04-25 1975-11-04 Alza Corp Osmotic dispensing device with maximum and minimum sizes for the passageway
US4008719A (en) * 1976-02-02 1977-02-22 Alza Corporation Osmotic system having laminar arrangement for programming delivery of active agent
DE2628202A1 (de) * 1976-06-23 1977-12-29 Max Planck Gesellschaft Verfahren zur herstellung von 2'-substituierten-d-ribofuranosylpurinderivaten
US4210745A (en) * 1978-01-04 1980-07-01 The United States Of America As Represented By The Department Of Health, Education And Welfare Procedure for the preparation of 9-β-D-arabinofuranosyl-2-fluoroadenine
US4188378A (en) * 1978-01-04 1980-02-12 The United States Of America As Represented By The Department Of Health, Education And Welfare Anticancer and antiviral activity of 9-β-D-arabinofuranosyl-2-fluoroadenine
ZA791659B (en) * 1978-04-17 1980-04-30 Ici Ltd Process and apparatus for spraying liquid
US4357324A (en) * 1981-02-24 1982-11-02 The United States Of America As Represented By The Department Of Health And Human Services Prodrug derivatives of 9β-D-arabinofuranosyl-2-fluoroadenine
IE58110B1 (en) * 1984-10-30 1993-07-14 Elan Corp Plc Controlled release powder and process for its preparation
GB8504253D0 (en) * 1985-02-19 1985-03-20 Ici Plc Electrostatic spraying apparatus
US4751221A (en) * 1985-10-18 1988-06-14 Sloan-Kettering Institute For Cancer Research 2-fluoro-arabinofuranosyl purine nucleosides
US5310732A (en) * 1986-02-03 1994-05-10 The Scripps Research Institute 2-halo-2'-deoxyadenosines in the treatment of rheumatoid arthritis
US5106837A (en) * 1988-03-16 1992-04-21 The Scripps Research Institute Adenosine derivatives with therapeutic activity
WO1989008658A1 (fr) * 1988-03-16 1989-09-21 Scripps Clinic And Research Foundation Derives d'adenine substitues utiles en tant qu'agents therapeutiques
DE3815221C2 (de) * 1988-05-04 1995-06-29 Gradinger F Hermes Pharma Verwendung einer Retinol- und/oder Retinsäureester enthaltenden pharmazeutischen Zubereitung zur Inhalation zur Einwirkung auf die Schleimhäute des Tracheo-Bronchialtraktes einschließlich der Lungenalveolen
US5073543A (en) * 1988-07-21 1991-12-17 G. D. Searle & Co. Controlled release formulations of trophic factors in ganglioside-lipsome vehicle
IT1229203B (it) * 1989-03-22 1991-07-25 Bioresearch Spa Impiego di acido 5 metiltetraidrofolico, di acido 5 formiltetraidrofolico e dei loro sali farmaceuticamente accettabili per la preparazione di composizioni farmaceutiche in forma a rilascio controllato attive nella terapia dei disturbi mentali organici e composizioni farmaceutiche relative.
US5034518A (en) * 1989-05-23 1991-07-23 Southern Research Institute 2-fluoro-9-(2-deoxy-2-fluoro-β-D-arabinofuranosyl) adenine nucleosides
US5384310A (en) * 1989-05-23 1995-01-24 Southern Research Institute 2'-fluoro-2-haloarabinoadinosines and their pharmaceutical compositions
US5120548A (en) * 1989-11-07 1992-06-09 Merck & Co., Inc. Swelling modulated polymeric drug delivery device
US5733566A (en) * 1990-05-15 1998-03-31 Alkermes Controlled Therapeutics Inc. Ii Controlled release of antiparasitic agents in animals
GB9125660D0 (en) * 1991-12-03 1992-01-29 Smithkline Beecham Plc Novel compound
US5580578A (en) * 1992-01-27 1996-12-03 Euro-Celtique, S.A. Controlled release formulations coated with aqueous dispersions of acrylic polymers
US5591767A (en) * 1993-01-25 1997-01-07 Pharmetrix Corporation Liquid reservoir transdermal patch for the administration of ketorolac
AU7470794A (en) * 1994-05-26 1995-12-21 Scripps Research Institute, The 2-halo-2'-deoxyadenosine treatement for inflammatory bowel disease
IT1270594B (it) * 1994-07-07 1997-05-07 Recordati Chem Pharm Composizione farmaceutica a rilascio controllato di moguisteina in sospensione liquida
US5970974A (en) * 1995-03-14 1999-10-26 Siemens Aktiengesellschaft Dosating unit for an ultrasonic atomizer device
EP0814860B1 (fr) * 1995-03-14 1999-11-03 Siemens Aktiengesellschaft Atomiseur a ultrasons pourvu d'une unite de dosage precis amovible
US5954047A (en) * 1997-10-17 1999-09-21 Systemic Pulmonary Development, Ltd. Methods and apparatus for delivering aerosolized medication
AU2002250236A1 (en) * 2001-03-02 2002-09-19 Medimmune, Inc. Cd2 antagonists for treatment of autoimmune or inflammatory disease
CA2439852A1 (fr) * 2001-03-02 2002-09-12 Christine Dingivan Prevention ou traitement de troubles inflammatoires ou auto-immuns par l'administration d'antagonistes de l'integrine alphav beta3
WO2004029025A2 (fr) * 2002-09-27 2004-04-08 Bioenvision, Inc. Methodes et compositions pour traiter des troubles auto-immunes a l'aide de clofarabine

Also Published As

Publication number Publication date
EP1551386A4 (fr) 2009-03-25
WO2004028463A2 (fr) 2004-04-08
US20090297478A1 (en) 2009-12-03
US20060135463A1 (en) 2006-06-22
CA2500091A1 (fr) 2004-04-08
EP1551386A2 (fr) 2005-07-13
AU2003276987A1 (en) 2004-04-19
AU2003276987B2 (en) 2009-07-30
WO2004028463A3 (fr) 2004-07-15

Similar Documents

Publication Publication Date Title
Hajhosseini et al. Hyperbaric oxygen therapy: descriptive review of the technology and current application in chronic wounds
NO20052348L (no) Behandling av hemoragisk sjokk
NO20072352L (no) Forbindelser og sammensetninger som inhibitorer av cannabinoidreceptor 1-aktivitet
MXPA05004778A (es) Metodos de uso y composiciones que contienen compuestos inmunomoduladores para el tratamiento y manejo de enfermedades mieloproliferativas.
NO20055863L (no) W-karboksyarylsubstituerte difenylureaforbindelser som raf-kinaseinhibitorer
BRPI0510627A (pt) combinações que compreendem um agonista do receptor s1p e um inibidor da jak3 quinase
NO20061092L (no) Heteroarvlaminosulfonvlfenvl-derivater for anvendelse som natrium- eller kalslumkanalblokkere i behandlingen av smerte
WO2004104166A3 (fr) Methodes permettant de faciliter la recuperation de fonctions de cellules souches endogenes, implantees ou transplantees au moyen d'un acide hyaluronique de poids moleculaire eleve
EA200401043A1 (ru) Лечение доброкачественной гиперплазии простаты селективным модулятором рецептора андрогенов ( sarm )
WO2003047504A3 (fr) Prevention et traitement de l'osteoporose induite par la privation d'androgene
NO20050827L (no) Anvendelse av interferon-B ved behandling av nyresvikt
NO20022221L (no) En fremgangsmåte til en kjemisk forhindring av prostatakreft
WO2003013430A3 (fr) Ansamycine benzoquinone
WO2006106311A3 (fr) Methodes de traitement combinees
NO20053111L (no) Peptider som inhiberer angiogenese, cellemigrering, celleinvasjon og celleproliferering.
NO20052040L (no) Fremgangsmater og sammensetninger for behandling av autoimmune forstyrrelser ved anvendelse av clofarabine
IN2005KO00312A (fr)
MX2009003532A (es) Tratamiento de hiperbilirrubinemia infantil utilizando bajas dosis de estansoporfina.
Winchester et al. Angina treatments and prevention of cardiac events: an appraisal of the evidence
NO20052039L (no) Fremgangsmater og sammensetninger for behandling av lupus ved anvendelse av clorfarabine
WO2004043336A3 (fr) Methodes d'utilisation d'agents inhibiteurs selectifs de la cytokine et compositions comprenant ces agents pour le traitement et la gestion de maladies myeloproliferatives
EA200901145A1 (ru) Применение рибофлавина в лечении гипертензии
EA200700690A1 (ru) Лечение остеопороза, индуцированного андрогенной депривацией
TW200501958A (en) A therapeutic agent for treating a behavioral disorder
GB0211230D0 (en) Treatment of heart failure

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application